clinical trial · NCT04530981
A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST
Deciphera Pharmaceuticals, LLC·phase1·completed·n = 13
GIST - Gastrointestinal Stromal TumorRipretinibRepaglinide
brief summary
Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Substrate
started
Sep 22, 2021
primary completion
Nov 16, 2023
completion
Jul 29, 2024
last updated
Sep 19, 2024
official title
A Phase 1 Open-label, Multicenter Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate (Repaglinide) in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol